Bladder cancer is the fifth most common cancer in the western world. MDxHealth developed a urine-based bladder cancer test for patients with hematuria (blood in urine). The test will provide physicians with a cost-effective, patient-friendly diagnostic tool to accurately detect bladder cancer and monitor recurrence.
A cohort study of 154 patients with hematuria showed that the test has a negative predictive value of 98.3%. The test is based on a combination of DNA methylation biomarkers, that were developed by MDxHealth and University Erasmus Medical Center. The latter party will receive milestone payments and royalties from MDxHealth.
